Results 61 to 70 of about 1,754,713 (289)

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

open access: yesAdvanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang   +8 more
wiley   +1 more source

DUET‐seq: An Open‐Source Droplet Platform for High‐Fidelity Joint Chromatin and Transcriptome Profiling Reveals Temporal Regulatory Decoupling in Single Cells

open access: yesAdvanced Science, EarlyView.
DUET‐seq is an open‐source droplet platform that jointly profiles chromatin accessibility and gene expression from the same nucleus. Dissolvable dual‐linker hydrogel beads and a one‐step intra‐droplet RT‐PCR co‐index both modalities in under 12 h at roughly $0.04 per cell.
Dong Cheng   +16 more
wiley   +1 more source

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer

open access: yesMedicina
Androgen deprivation therapy (ADT) is a mainstay treatment for metastatic prostate cancer, improving progression-free survival. ADT suppresses the production of testosterone and reduces circulating levels of the hormone.
Allison B. Reiss   +7 more
doaj   +1 more source

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding

open access: yesBMC Genomics, 2012
Background The androgen receptor plays a critical role throughout the progression of prostate cancer and is an important drug target for this disease. While chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-Seq) is becoming ...
Zhu Zhou   +10 more
doaj   +1 more source

Drug Repurposing for Treating NCOR‐Related Intellectual Disability

open access: yesAdvanced Science, EarlyView.
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong   +15 more
wiley   +1 more source

Decoding Biomolecular Phase Separation: From Physiological Roles to Pathological Mechanisms and Therapeutic Biomaterials Design

open access: yesAdvanced Science, EarlyView.
This review systematically elaborates on the mechanisms underlying physiological regulation and pathological dysregulation of biomolecular phase separation. It also summarizes advances in phase‑separation‑targeted therapeutic strategies and the design of functional biomaterials inspired by this process.
Jiawei Zhu   +5 more
wiley   +1 more source

Design and Synthesis of 4‑(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists

open access: yes, 2016
We report the design and synthesis of novel 4-(4-benzoylaminophenoxy)­phenol derivatives that bind to the androgen receptor (AR) ligand-binding domain and exhibit potent androgen-antagonistic activity.
Shuichi Mori (362273)   +3 more
core   +2 more sources

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

open access: yesDrug Design, Development and Therapy, 2021
Yi-Fu Liu, Sheng-Qiang Fu, Yu-Chang Yan, Bin-Bin Gong, Wen-Jie Xie, Xiao-Rong Yang, Ting Sun, Ming Ma Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, 330000, Jiangxi Province, People’s Republic of ...
Liu YF   +7 more
doaj  

Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells

open access: yesProstate Cancer, 2020
Interleukin-10 (IL10) is best studied for its inhibitory action on immune cells and ability to suppress an antitumour immune response. But IL10 also exerts direct effects on nonimmune cells such as prostate cancer epithelial cells.
Abrar Samiea   +5 more
doaj   +1 more source

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. [PDF]

open access: yesPLoS ONE, 2017
Androgen receptor (AR) is a member of the steroid receptor family and a therapeutic target for all stages of prostate cancer. AR is activated by ligand binding within its C-terminus ligand-binding domain (LBD).
Jae-Kyung Myung   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy